Fig. 2
From: SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
Downregulation of SMARCA4 drives the observed switch to SMARC2 in the SWI/SNF complex. a, b SMARC4 knockdown in parental ARID1A-mutated TOV21G cells increases SMARCA2 levels (a) and desensitizes parental cells to GSK126 treatment (5 μM) (b). c, d Ectopic SMARCA4 expression in resistant cells decreases SMARCA2 levels (c) and resensitizes resistant cells to GSK126 (10 μM) (d). e Co-immunoprecipitation analysis using an antibody to core subunit SMARCC1 shows the switch of the catalytic subunit from SMARCA4 to SMARCA2 in TOV21G cells with or without SMARCA4 knockdown. f Sucrose sedimentation (10–50%) assay of SWI/SNF complex from TOV21G cells with or without SMARCA4 knockdown. Data represent mean ± S.E.M. of three independent experiments (a–e). P-value was calculated via two-tailed t-test
